Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.

Julia Maria ResslerMatthias KarasekLukas KochRita SilmbrodJoanna ManganaSofiya LatifyanVeronica Aedo-LopezHelmut KehrerFelix WeihsengruberPeter KoelblingerChristian PoschJulian KoflerOlivier MichielinErika RichtigChristine HafnerChristoph Hoeller

Published in: Journal for immunotherapy of cancer (2022)

This real-life cohort treatment with T-VEC showed a high ORR and a large number of durable CRs.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
patient reported outcomes
combination therapy
replacement therapy